Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2026)

Crinetics Pharmaceuticals' Accounts Payables history runs 10 years deep, the most recent figure standing at $37.5 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 18.57% year-over-year to $37.5 million in Q1 2026; TTM through Mar 2026 was $37.5 million, a 18.57% increase from a year earlier, with the FY2025 full-year figure at $41.8 million, up 94.56% from the prior year.
• Accounts Payables slipped to $37.5 million in Q1 2026 per CRNX's latest filing, from $41.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $41.8 million in Q4 2025 and bottomed at $4.9 million in Q3 2024.
• The 5-year median for Accounts Payables is $21.9 million (2023), against an average of $22.1 million.
• Across the five-year window, Accounts Payables plunged 77.48% in 2024 and jumped 581.8% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $6.9 million in 2022, then soared by 237.0% to $23.2 million in 2023, then slipped by 7.45% to $21.5 million in 2024, then surged by 94.56% to $41.8 million in 2025, then slipped by 10.25% to $37.5 million in 2026.
• Per Business Quant, the three latest CRNX Accounts Payables figures stand at $37.5 million (Q1 2026), $41.8 million (Q4 2025), and $33.7 million (Q3 2025).